#China #Shenzhen #diabetes management #SIBIONICS #AGP Reporting

SIBIONICS Hosts the 3rd AGP DTx Summit Forum

On May 31, 2025, SIBIONICS hosted the third AGP DTx Summit Forum in Shenzhen, China, marking a significant event in the realm of diabetes care. This forum convened over 100 specialists from across the globe who are dedicated to innovating the future of diabetes management.

The main agenda focused on "Milestones and Future Strategies of the Project on Standardizing Nursing Practices in AGP Reporting", providing an in-depth look at the current landscape and future directions of digital diabetes management.

Highlights of the Summit

A focal point of the summit was the launch of a Continuous Glucose Monitoring (CGM) donation program in collaboration with March of Dimes China. This initiative aims to supply children living with Type 1 diabetes with free devices, facilitating better management of their condition.

Parallel Sessions on Clinical Innovations

In addition to the main discussions, parallel sessions delved into clinical CGM+X solutions and the implementation of AGP and Digital Therapeutics (DTx) technologies. Key topics included:

• - Optimizing Treatments: The essential role of CGM in enhancing treatment plans involving novel insulin formulations.
• - Innovative Developments: New advancements in artificial pancreas systems designed to improve patient outcomes.

Workshops and Influencer Engagement

Workshop sessions explored how CGM can enhance clinical care practices. Simultaneously, influencers were invited to tour the SIBIONICS manufacturing facility, where they shared personal experiences and had the opportunity to test the latest CGM products.

Exhibition: “Evolution & Renewal”

Accompanying the forum was an exhibition titled "Evolution & Renewal", which traced the historical development of diabetes management. This exhibition highlighted how modern CGM technology empowers individuals to lead healthier, more liberated lives.

Strengthening Global Partnerships

Concurrent to the forum, SIBIONICS also held its second Global Partnership Summit, inviting international distributors to enhance collaboration and accelerate global outreach.

Looking to the Future

Through the integration of AGP reporting with CGM innovations, SIBIONICS is paving the way for a smarter, more accessible, and more effective future in diabetes care. The company’s ongoing commitment is to translate technology into practical solutions that support healthcare professionals, inspire patients, and create an environment where diabetes no longer limits human potential.

About SIBIONICS

Founded in 2015, SIBIONICS is a pioneering medical device company based in Shenzhen and Irvine. It specializes in innovations related to biosensors, merging continuous monitoring technology, intelligent algorithms, and user-friendly software to enhance health management. With a team of over 500 employees, including 25% in research and development, SIBIONICS is dedicated to advancing personalized, data-driven healthcare.